FDA Inspection 1321196 — Rafal Drozda
The FDA completed an inspection of Rafal Drozda on May 21, 2026 in Lodz. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- May 21, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Lodz (Poland)
Additional Details
Clinical Investigator (CI)